谢方云

一、基本情况

职称：教授、主任医师、博士生导师

专业特长：鼻咽癌、头颈部肿瘤的临床诊断、精准放射治疗及综合治疗优化。

专家门诊时间：越秀院区：周二下午、周三上午 黄埔院区：周四上午

主攻方向如下：①证明了TPF、GP及卡培他滨维持化疗等方案在鼻咽癌的有效性，成果分别发表在Lancet Oncology、NEJM、Lancet等肿瘤学顶尖期刊，改写了鼻咽癌的国际治疗指南；②正在承担鼻咽癌及头颈肿瘤的免疫治疗联合放化疗的临床研究；③我院头颈部肿瘤放疗大PI，广东省医师协会放疗专业委员会第一、二届头颈组组长，在鼻咽癌及头颈肿瘤的调强放射治疗及综合治疗优化已有40余年的经验。

二、学习及工作经历

1980.09-1985.07湖南医学院（现中南大学湘雅医学院） 临床医学 获学士学位

1985.07-2002.08中山大学肿瘤防治中心 放疗科 住院医师、主治医师

1990.09-1994.07中山医科大学 肿瘤学 获硕士学位

2002.08-至今 中山大学肿瘤防治中心 放疗科 副主任医师、主任医师、教授

三、学术兼职

广东省医师协会放射治疗专业委员会第一、二届副主任委员

广东省医师协会放射治疗专业委员会第一、二届头颈肿瘤专业组组长

广东省临床医学学会头颈肿瘤综合治疗专业委员会副主任委员

中国临床肿瘤学会（CSCO）鼻咽癌专业委员会委员

粤港澳大湾区放射治疗医师联盟副主任

中国肿瘤放射治疗联盟放射免疫工作委员会副主任委员

中国肿瘤放射治疗联盟放射免疫工作委员会广东分会主任委员

四、获奖情况

(1) 鼻咽癌综合诊疗方案的创立与临床应用2021年广东省科技进步一等奖

(2) 鼻咽癌精准诊疗方案的建立与应用2020年教育部高校科技进步奖一等奖

(3) 提高鼻咽癌疗效的关键技术与应用2020年 广东省医学科学技术奖一等奖

(4) 鼻咽癌诊疗关键策略研究与应用 2015年 国家科学技术进步奖二等奖

(5) 鼻咽癌个体化治疗研究与应用 2014年 中华医学科技奖一等奖

(6) 鼻咽癌个体化治疗研究与应用 2014年 高等教育部科技进步奖一等奖

(7) 鼻咽癌个体化治疗研究与应用 2014年 广东省科学技术奖励一等奖

五、主持科研项目

①国家自然科学基金重点项目cdh1(FZR1)磷酸化新点被调控的机理，对功能的影响及其意义(2009-2013年，第2负责人)

②国家自然科学基金面上项目 Fli-1靶向上调VEGF-C促进鼻咽癌转移的分子机制和临床意义研究（2017-2020年第1负责人）

③广东省自然科学基金Fli-1靶向调控VEGF-C促进鼻咽癌生长和转移的研究（2017-2020，第1负责人）

④广东省科学技术厅多西他赛加顺铂（TP）对比单药顺铂（DDP）的同期化疗联合调强放疗治疗高危局部区域晚期鼻咽癌的随机对照II期临床研究（2016-2018年，第1负责人）

⑤中山大学5010项目调强放疗加或不加同期化疗治疗II期鼻咽癌的非劣效性、随机对照、多中心III期临床研究（2015-2025年，第1负责人）

五、代表性论著

[1]Tang L L, Chen L, Xu G Q, Zhang N, Huang C L, Li W F, Mao Y P, Zhou G Q, Lei F, Chen L S, Huang S H, Chen L, Chen Y P, Zhang Y, Liu X, Xu C, Zhao Y, Li J B, Liu N, Xie F Y, Guo R, Sun Y, Ma J. Reduced-volume radiotherapy versus conventional-volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open-label, noninferiority, multicenter, randomized phase 3 trial [J]. CA Cancer

[2]Chen YP, Liu X, Zhou Q, Yang KY, Jin F, Zhu XD, Shi M, Hu GQ, Hu WH, Sun Y, Wu HF, Wu H, Lin Q, Wang H, Tian Y, Zhang N, Wang XC, Shen LF, Liu ZZ, Huang J, Luo XL, Li L, Zang J, Mei Q, Zheng BM, Yue D, Xu J, Wu SG, Shi YX, Mao YP, Chen L, Li WF, Zhou GQ, Sun R, Guo R, Zhang Y, Xu C, Lv JW, Guo Y, Feng HX, Tang LL, Xie FY, Sun Y, Ma J.Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.Lancet

[3]Liu X, Zhang Y, Yang KY, Zhang N, Jin F, Zou GR, Zhu XD, Xie FY, Liang XY, Li WF, He ZY, Chen NY, Hu WH, Wu HJ, Shi M, Zhou GQ, Mao YP, Guo R, Sun R, Huang J, Liang SQ, Wu WL, Su Z, Li L, Ai P, He YX, Zang J, Chen L, Lin L, Huang SH, Xu C, Lv JW, Li YQ, Hong SB, Jie YS, Li H, Huang SW, Liang YL, Wang YQ, Peng YL, Zhu JH, Zang SB, Liu SR, Lin QG, Li HJ, Tian L, Liu LZ, Zhao HY, Lin AH, Li JB, Liu N, Tang LL, Chen YP, Sun Y, Ma J.Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.

[4]Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, Jin F, Shi M, Chen YP, Hu WH, Cheng ZB, Wang SY, Tian Y, Wang XC, Sun Y, Li JG, Li WF, Li YH, Tang LL, Mao YP, Zhou GQ, Sun R, Liu X, Guo R, Long GX, Liang SQ, Li L, Huang J, Long JH, Zang J, Liu QD, Zou L, Su QF, Zheng BM, Xiao Y, Guo Y, Han F, Mo HY, Lv JW, Du XJ, Xu C, Liu N, Li YQ, Chua MLK, Xie FY, Sun Y, Ma J.Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma.N Engl J Med

[5]Liang Y L, Liu X, Shen L F, Hu G Y, Zou G R, Zhang N, Chen C B, Chen X Z, Zhu X D, Yuan Y W, Yang K Y, Jin F, Hu W H, Xie F Y, Huang Y, Han F, Tang L L, Mao Y P, Lu L X, Sun R, He Y X, Zhou Y Y, Long G X, Tang J, Chen L S, Zong J F, Jin T, Li L, Lin J, Huang J, Gong X Y, Zhou G Q, Chen L, Li W F, Chen Y P, Xu C, Lin L, Huang S H, Huang S W, Wang Y Q, Huang C L, Feng H X, Hou M, Chen C H, Zheng S F, Li Y Q, Hong S B, Jie Y S, Li H, Yun J P, Zang S B, Liu S R, Lin Q G, Li H J, Tian L, Liu L Z, Zhao H Y, Li J B, Lin A H, Liu N, Zhang Y, Guo R, Ma J, Sun Y. Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma: The DIPPER Randomized Clinical Trial [J]. Jama

[6]Xu C, Liang X Y, Huang X Q, Jin F, Yang K Y, Hu G Y, Zhu X D, Wang Y, Huang Y, Zhang N, Hu D S, Guo L, Zou G R, Chen X Z, Xiao S W, Li J G, Shen L F, Li Y Y, Huang J, Long G X, Li L, Huang L, She L J, Wu Y, Zeng W H, Qiang M Y, Liu W X, Su Y, Tang L L, Xie F Y, Han F, Lu L X, Xiang Y Q, Mao Y P, Li W F, Liu X, Yang Q, Zhou G Q, Guo R, Ouyang P Y, Wang X H, Chen L, Liu L T, Lin L, Li J B, Lin A H, Zhao H Y, Hong S B, Jie Y S, Huang H L, Tang X H, Zeng Y C, Yun J P, Zang S B, Du Z M, Ye Z L, Liu L Z, Tian L, Li H J, Peng Y L, Liu N, Li Y Q, Liang Y L, Wei H M, Chen Y P, Zhang Y, Du X J, Lv J W, Sun Y, Ma J. Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma: The DIAMOND Randomized Clinical Trial [J]. Jama.

[7]Mao YP, Wang SX, Gao TS, Zhang N, Liang XY, Xie FY, Zhang Y, Zhou GQ, Guo R, Luo WJ, Li YJ, Liang SQ, Lin L, Li WF, Liu X, Xu C, Chen YP, Lv JW, Huang SH, Liu LZ, Li JB, Tang LL, Chen L, Sun Y, Ma J.Medial retropharyngeal nodal region sparing radiotherapy versus standard radiotherapy in patients with nasopharyngeal carcinoma: open label, non-inferiority, multicentre, randomised, phase 3 trial.BMJ

[8]Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, Jin F, Shi M, Chen YP, Hu WH, Cheng ZB, Wang SY, Tian Y, Wang XC, Sun Y, Li JG, Li WF, Li YH, Mao YP, Zhou GQ, Sun R, Liu X, Guo R, Long GX, Liang SQ, Li L, Huang J, Long JH, Zang J, Liu QD, Zou L, Su QF, Zheng BM, Xiao Y, Guo Y, Han F, Mo HY, Lv JW, Du XJ, Xu C, Liu N, Li YQ, Xie FY, Sun Y, Ma J, Tang LL.Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III Trial.J Clin Oncol.

[9]Huang CL, Zhang N, Jiang W, Xie FY, Pei XQ, Huang SH, Wang XY, Mao YP, Li KP, Liu Q, Li JB, Liang SQ, Qin GJ, Hu WH, Zhou GQ, Ma J, Sun Y, Chen L, Tang LL.Reduced-Volume Irradiation of Uninvolved Neck in Patients With Nasopharyngeal Cancer: Updated Results From an Open-Label, Noninferiority, Multicenter, Randomized Phase III Trial.Clin Oncol.

[10]Tang LL, Huang CL, Zhang N, Jiang W, Wu YS, Huang SH, Mao YP, Liu Q, Li JB, Liang SQ, Qin GJ, Hu WH, Sun Y, Xie FY, Chen L, Zhou GQ, Ma J.Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial.Lancet Oncol.

[11]OuYang PY, You KY, Zhang LN, Xiao Y, Zhang XM, Xie FY.External validity of a prognostic nomogram for locoregionally advanced nasopharyngeal carcinoma based on the 8th edition of the AJCC/UICC staging system: a retrospective cohort study.Cancer Commun

[12]Chen E, Wu J, Huang J, Zhu W, Sun H, Wang X, Lin D, Li X, Shi D, Liu Z, Huang J, Chen M, Xie F, Deng W.FLI1 promotes IFN-γ-induced kynurenine production to impair anti-tumor immunity.Nat Commun[13]Qin G, Wang X, Ye S, Li Y, Chen M, Wang S, Qin T, Zhang C, Li Y, Long Q, Hu H, Shi D, Li J, Zhang K, Zhai Q, Tang Y, Kang T, Lan P, Xie F, Lu J, Deng W.NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer.Nat Commun

[14]Liao Y, Hua Y, Li Y, Zhang C, Yu W, Guo P, Zou K, Li W, Sun Y, Wang R, Zuo Y, Sui S, Tian C, Hao J, CDeng W.CRSP8 promotes thyroid cancer progression by antagonizing IKKα-induced hen M, Hu S, Chen M, Long Q, Wang X, Zou L, Xie F, Guo W, CRSP8 promotes thyroid cancer progression by antagonizing IKKα-induced cell differentiation.cell differentiation.Cell Death Differ

[15]Tian T, Chen ZH, Zheng Z, Liu Y, Zhao Q, Liu Y, Qiu H, Long Q, Chen M, Li L, Xie F, Luo G, Wu X, Deng W.Investigation of the role and mechanism of ARHGAP5-mediated colorectal cancer metastasis.Theranostics

[16]OuYang PY, Zhang BY, Guo JG, Liu JN, Li J, Peng QH, Yang SS, He Y, Liu ZQ, Zhao YN, Li A, Wu YS, Hu XF, Chen C, Han F, You KY, Xie FY.Deep learning-based precise prediction and early detection of radiation-induced temporal lobe injury for nasopharyngeal carcinoma.EClinicalMedicine.

[17]OuYang PY, He Y, Guo JG, Liu JN, Wang ZL, Li A, Li J, Yang SS, Zhang X, Fan W, Wu YS, Liu ZQ, Zhang BY, Zhao YN, Gao MY, Zhang WJ, Xie CM, Xie FY.Artificial intelligence aided precise detection of local recurrence on MRI for nasopharyngeal carcinoma: a multicenter cohort study.EClinicalMedicine.

[18]Long Q, Hua Y, He L, Zhang C, Sui S, Li Y, Qiu H, Tian T, An X, Luo G, Yan Y, Zhao A, Shi D, Xie F, Chen M, Zheng F, Deng W.Poly(U) binding splicing factor 60 promotes renal cell carcinoma growth by transcriptionally upregulating telomerase reverse transcriptase.Int J Biol Sci.

[19]Yang SS, Wu YS, Chen WC, Zhang J, Xiao SM, Zhang BY, Liu ZQ, Chen EN, Zhang X, OuYang PY, Xie FY.Benefit of [18F]-FDG PET/CT for treatment-naïve nasopharyngeal carcinoma.Eur J Nucl Med

[20]OuYang PY, Liu ZQ, Lin QG, He Y, Guo ZX, Yao WY, Xu SK, Peng QH, Xiao SM, Li J, Li A, Zhang BY, Yang SS, Fan W, Xie CM, Wu YS, Zhang X, Chen CY, Xie FY.Benefit of [(18)F] FDG PET/CT in the diagnosis and salvage treatment of recurrent nasopharyngeal carcinoma.Eur J Nucl Med .

[21]Chen E, Huang J, Chen M, Wu J, Ouyang P, Wang X, Shi D, Liu Z, Zhu W, Sun H, Yang S, Zhang B, Deng W, Qiu H, Xie F.FLI1 regulates radiotherapy resistance in nasopharyngeal carcinoma through TIE1-mediated PI3K/AKT signaling pathway.J Transl Med.

[22]Lei Y, Li YQ, Jiang W, Hong XH, Ge WX, Zhang Y, Hu WH, Wang YQ, Liang YL, Li JY, Cho WCS, Yun JP, Zeng J, Chen JW, Liu LZ, Li L, Chen L, Xie FY, Li WF, Mao YP, Liu X, Chen YP, Tang LL, Sun Y, Liu N, Ma J.A Gene-Expression Predictor for Efficacy of Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma.J Natl Cancer Inst.

[23]Yang SS, OuYang PY, Guo JG, Cai JJ, Zhang J, Peng QH, He Y, Zhang BY, Liu ZQ, Hu XF, Chen YF, Chen CY, Xie FY.Dosiomics Risk Model for Predicting Radiation Induced Temporal Lobe Injury and Guiding Individual Intensity-Modulated Radiation Therapy.Int J Radiat Oncol Biol Phys.

[24]Liu X, Guo L, Xie FY, Hu WH, Chen MY, He QM, Xu ZM, Zhang CQ, Peng YL, Tang LL, Mao YP, Sun R, Li JB, Argiris A, Hui EP, Sun Y, Ma J.Adjuvant Apatinib in Nasopharyngeal Carcinoma With Residual Epstein-Barr Virus DNA After Radiation Therapy: A Biomarker-Driven, Phase 2 Trial.Int J Radiat Oncol Biol Phys.

[25]Wang J, Xiao X, Zhang Y, Shi D, Chen W, Fu L, Liu L, Xie F, Kang T, Huang W, Deng W.Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells.J Pineal Res.

[26]Shi D, Xiao X, Wang J, Liu L, Chen W, Fu L, Xie F, Huang W, Deng W.Melatonin suppresses proinflammatory mediators in lipopolysaccharide-stimulated CRL1999 cells via targeting MAPK, NF-κB, c/EBPβ, and p300 signaling.J Pineal Res.

[27]Liu ZQ, Feng YF, Xiao Y, Zhang XM, Li JB, Xie FY, Mao YP.Clinical characteristics, prognostic factors, and treatment modalities for head and neck lymphoepithelioma-like carcinoma: A real-world study from southern China.Radiother Oncol.

[28]Liu Z Q, Zang S B, OuYang P Y, Jing B Z, Zheng C Y, Zhao Y N, Chen H H, Wang Y T, Wang H M, Zhang W J, Zhang J Y, Xu X W, Wang S Y, Lin Y J, Yun J P, Xie F Y. Multimodal prognostic model for de novo metastatic nasopharyngeal carcinoma after first-line immunochemotherapy [J]. Radiother Oncol

[29]Lu JJ, Fu L, Tang Z, Zhang C, Qin L, Wang J, Yu Z, Shi D, Xiao X, Xie F, Huang W, Deng W.Melatonin inhibits AP-2β/hTERT, NF-κB/COX-2 and Akt/ERK and activates caspase/Cyto C signaling to enhance the antitumor activity of berberine in lung cancer cells.Oncotarget.

[30]Shi D, Xiao X, Tian Y, Qin L, Xie F, Sun R, Wang J, Li W, Liu T, Xiao Y, Yu W, Guo W, Xiong Y, Qiu H, Kang T, Huang W, Zhao C, Deng W.Activating enhancer-binding protein-2α induces cyclooxygenase-2 expression and promotes nasopharyngeal carcinoma growth.Oncotarget.